ENXTPA:SIGHT

Stock Analysis Report

Executive Summary

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Share Price & News

How has GenSight Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SIGHT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

11.8%

SIGHT

-3.9%

FR Biotechs

0.02%

FR Market


1 Year Return

-51.0%

SIGHT

-33.9%

FR Biotechs

18.9%

FR Market

Return vs Industry: SIGHT underperformed the French Biotechs industry which returned -33.9% over the past year.

Return vs Market: SIGHT underperformed the French Market which returned 18.9% over the past year.


Shareholder returns

SIGHTIndustryMarket
7 Day11.8%-3.9%0.02%
30 Day3.4%4.1%4.7%
90 Day-13.7%-13.3%7.3%
1 Year-51.0%-51.0%-33.8%-33.9%22.9%18.9%
3 Year-84.5%-84.5%-60.0%-60.0%49.5%35.3%
5 Yearn/a-62.5%-63.0%66.7%43.1%

Price Volatility Vs. Market

How volatile is GenSight Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GenSight Biologics undervalued compared to its fair value and its price relative to the market?

2.27x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SIGHT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SIGHT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SIGHT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SIGHT is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SIGHT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SIGHT is overvalued based on its PB Ratio (2.3x) compared to the FR Biotechs industry average (1.9x).


Next Steps

Future Growth

How is GenSight Biologics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-1.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SIGHT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SIGHT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SIGHT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SIGHT's revenue (39.1% per year) is forecast to grow faster than the French market (4.6% per year).

High Growth Revenue: SIGHT's revenue (39.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SIGHT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has GenSight Biologics performed over the past 5 years?

-30.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SIGHT has high quality earnings.

Growing Profit Margin: SIGHT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SIGHT is unprofitable, and losses have increased over the past 5 years at a rate of -30.2% per year.

Accelerating Growth: Unable to compare SIGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SIGHT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: SIGHT has a negative Return on Equity (-255.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is GenSight Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: SIGHT's short term assets (€25.2M) exceeds its short term liabilities (€8.7M)

Long Term Liabilities: SIGHT's short term assets (€25.2M) exceeds its long term liabilities (7.0M)


Debt to Equity History and Analysis

Debt Level: SIGHT's debt to equity ratio (23.1%) is considered satisfactory.

Reducing Debt: SIGHT's debt to equity ratio has increased from 2.3% to 23.1% over the past 5 years.


Balance Sheet

Inventory Level: SIGHT has a low level of unsold assets or inventory.

Debt Coverage by Assets: SIGHT's debt is covered by short term assets (assets are 7.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SIGHT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SIGHT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -21.6% each year


Next Steps

Dividend

What is GenSight Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%4.5%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate SIGHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SIGHT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SIGHT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIGHT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SIGHT's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

What is the CEO of GenSight Biologics's salary, the management and board of directors tenure and is there insider trading?

3.2yrs

Average management tenure


CEO

Bernard Gilly (62yo)

7.8yrs

Tenure

€628,518

Compensation

Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He is Independent Chairman at EyeTechCare SA. He serves as President and Chairman of the Board at ChronoLife SAS. He co-founded Fovea Pharmaceutical ...


CEO Compensation Analysis

Compensation vs Market: Bernard's total compensation ($USD696.42K) is above average for companies of similar size in the French market ($USD158.33K).

Compensation vs Earnings: Bernard's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.2yrs

Average Tenure

Experienced Management: SIGHT's management team is considered experienced (3.2 years average tenure).


Board Age and Tenure

7.6yrs

Average Tenure

64yo

Average Age

Experienced Board: SIGHT's board of directors are considered experienced (7.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.1%.


Management Team

  • Bernard Gilly (62yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: €628.52k
  • José-Alain Sahel

    Scientific Founder

    • Tenure: 0yrs
  • Barrett Katz

    Consultant

    • Tenure: 2.1yrs
  • Connie Cepko

    Scientific Founders & Member of Scientific Advisory Board

    • Tenure: 7.6yrs
  • Botond Roska

    Scientific Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Jean Bennett

    Scientific Founder & Vice Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Luk Vandenberghe

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.6yrs
  • Serge Picaud

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.6yrs
  • Thomas Gidoin (36yo)

    Chief Financial Officer

    • Tenure: 4.3yrs
  • Julio Benedicto

    Vice President of Marketing

    • Tenure: 1.8yrs

Board Members

  • Mike Wyzga (64yo)

    Independent Chairman of the Board

    • Tenure: 3.7yrs
    • Compensation: €165.35k
  • Bernard Gilly (62yo)

    Co-Founder

    • Tenure: 7.8yrs
    • Compensation: €628.52k
  • Peter Goodfellow (68yo)

    Independent Director

    • Tenure: 0yrs
    • Compensation: €60.00k
  • José-Alain Sahel

    Scientific Founder

    • Tenure: 0yrs
  • Connie Cepko

    Scientific Founders & Member of Scientific Advisory Board

    • Tenure: 7.6yrs
  • Botond Roska

    Scientific Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Jean Bennett

    Scientific Founder & Vice Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Luk Vandenberghe

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.6yrs
  • Serge Picaud

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.6yrs
  • Ernst Bamberg

    Member of Scientific Advisory Board

    • Tenure: 7.6yrs

Company Information

GenSight Biologics S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GenSight Biologics S.A.
  • Ticker: SIGHT
  • Exchange: ENXTPA
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €34.864m
  • Shares outstanding: 28.81m
  • Website: https://www.gensight-biologics.com

Number of Employees


Location

  • GenSight Biologics S.A.
  • 74, rue du Faubourg Saint-Antoine
  • Paris
  • Ile-de-France
  • 75012
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
G49NDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2016
SIGHTENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2016
0RIMLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2016
SIGHTPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2016
GSGT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2016

Biography

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and ce ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/19 22:00
End of Day Share Price2019/11/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.